Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease
-
- Matsuzaki Masunori
- Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
-
- Yokoyama Mitsuhiro
- Division of Cardiovascular and Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
-
- Saito Yasushi
- Department of Clinical Cell Biology Graduate School of Medicine, Chiba University
-
- Origasa Hideki
- Division of Biostatistics and Clinical Epidemiology, University of Toyama
-
- Ishikawa Yuichi
- Faculty of Health Sciences, Kobe University School of Medicine
-
- Oikawa Shinichi
- Division of Endocrinology and Metabolism, Department of Medicine, Nippon Medical School
-
- Sasaki Jun
- International University of Health and Welfare Graduate School of Public Health Medicine
-
- Hishida Hitoshi
- Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine
-
- Itakura Hiroshige
- Department of Food Science, Ibaraki Christian University, College of Life Science
-
- Kita Toru
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
-
- Kitabatake Akira
- Hiraoka Hospital
-
- Nakaya Noriaki
- Nakaya Clinic
-
- Sakata Toshiie
- Department of Nutritional Sciences, Faculty of Nutritional Science, Nakamura Gakuen University
-
- Shimada Kazuyuki
- Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical School
-
- Shirato Kunio
- Saito Hospital
-
- Matsuzawa Yuji
- Sumitomo Hospital
書誌事項
- タイトル別名
-
- Incremental Effects of Eicosapentaenoic Acid on Cardiovascular Events in Statin-Treated Patients With Coronary Artery Disease Secondary Prevention Analysis From JELIS
- Secondary Prevention Analysis From JELIS
この論文をさがす
説明
Background: Results from JELIS (Japan EPA Lipid Intervention Study) demonstrated the efficacy of pure eicosapentaenoic acid (EPA) in preventing coronary artery disease (CAD) in hypercholesterolemic patients under statin treatment. The present study examined in detail whether EPA is effective for the secondary prevention of CAD. Methods and Results: Patients with established CAD and a total cholesterol level ≥250 mg/dl were observed with a mean follow-up of 4.6 years. They were randomly assigned to receive either 1,800 mg of EPA + statin (EPA group) or statin alone (control group). The incidence of major coronary events (MCE) were compared in the 2 groups. The incidence of MCE was significantly lower in the EPA group (8.7% vs 10.7%, adjusted hazard ratio =0.77, 95% confidence interval (CI) 0.63-0.96, P=0.017, number needed to treat (NNT) =49). Among 1,050 patients with prior myocardial infarction (MI), the incidence of MCE in the EPA group (15.0%) was significantly lower than that in the control group (20.1%, adjusted hazard ratio =0.73, 95%CI 0.54-0.98, P=0.033, NNT =19). Conclusions: EPA is effective for secondary prevention of CAD, especially in individuals with prior MI, and should be added to conventional treatment. (Circ J 2009; 73: 1283-1290)<br>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 73 (7), 1283-1290, 2009
一般社団法人 日本循環器学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282680080311040
-
- NII論文ID
- 10025932638
-
- NII書誌ID
- AA11591968
-
- COI
- 1:CAS:528:DC%2BD1MXptVejsLw%3D
-
- ISSN
- 13474820
- 13469843
-
- PubMed
- 19423946
-
- 本文言語コード
- en
-
- 資料種別
- journal article
-
- データソース種別
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
- OpenAIRE
-
- 抄録ライセンスフラグ
- 使用不可
